Yizhou Dong,Kevin T. Love,J. Robert Dorkin,Sasilada Sirirungruang,Yunlong Zhang,Delai Chen,Roman L. Bogorad,Hao Yin,Yi Chen,Arturo J. Vegas,Christopher A. Alabi,Gaurav Sahay,Karsten Olejnik,Weiheng Wang,Avi Schroeder,Abigail K. R. Lytton‐Jean,Daniel J. Siegwart,Akin Akinc,Carmen Barnes,Scott Barros
Significance The safe, selective, and efficient delivery of siRNA is a key challenge to the broad application of siRNA therapeutics in humans. Motivated by the structure of lipoproteins, we developed lipopeptide nanomaterials for siRNA delivery. In vivo in mice, siRNA–lipopeptide particles provide the most potent delivery to hepatocytes (ED 50 ∼ 0.002 mg/kg for FVII silencing), with the highest selectivity of delivery to hepatocytes over nontarget cell types (orders of magnitude), yet reported. These materials also show efficacy in nonhuman primates.